Introduction and Objective: Overweight affects over 1 in 3 patients with T1D. The aim of this pilot study was to adapt our successful evidence-based Family-Based Behavioral Treatment (FBT) to treat overweight in youth with T1D and overweight and their parents with overweight. Methods: Coaches delivered 10 in-person/virtual sessions over 12 weeks to children age 6-17 yrs, BMI≥85th%, T1D duration≥1 yr, using pump and CGM and having 1 parent with BMI≥25Kg/m2. We excluded those with other chronic/autoimmune diseases (except thyroiditis), eating disorders, and therapies affecting weight. Participants received a Bluetooth scale to check home weight twice/week and MyNetDiary app to log dietary intake. Data were expressed as mean±SD. Changes from baseline were evaluated using two-sided one-sample t-tests of within-subject change scores. Results: Participants included 11 dyads: children (age 12.4±3 yrs.) and parents (age 45±5 yrs.). Youth had a % overweight≥50 percentile (%OW) decrease from 55.4±21 to 50.7±225% (p0.02). %OW was calculated as follows: (Child BMI-BMI@50th Percentile)/BMI@50th)x100. HbA1c and insulin dose were 7.7±0.5% and 1.00±0.2 U/Kg/day at baseline and remained stable at 12 weeks. Parents’ weight decreased from 243±41 lbs. to 237.5±39 (p=0.006) and did not correlate with change in %OW in children. The Diabetes Treatment Satisfaction Questionnaire score (range 1-72) was 48.5±4.8 at baseline and 55.3±4.9 (p=0.01) at 12 weeks in youth. Conclusion: FBT decreased %OW in children and weight in parents. The decrease in %OW in children and weight in parents are similar to those obtained in FBT implemented in primary care. The lack of correlation between parent and child weight changes suggests that parents did not model. Parents and children expressed satisfaction with the program, but reported difficulty affording healthy food. They checked their home weight but did not record dietary intake, being unwilling to add any additional duty to the already burdensome T1D. This needs to be considered in the approach to treating overweight in T1D. Disclosure T. Quattrin: Consultant; Ended; Provention Bio, Inc. Speaker's Bureau; Current; Sanofi. Advisory Panel; Current; Sanofi. Research Support; Current; National Center for Advancing Translational Sciences. A.W. Strohmeier: None. A.L. Barczykowski: None. C.K. Kilanowski: Employee; Current; Girls on the Run. Consultant; Current; Washington University. A. Reimer: None. M.L. Brooks: None. A. Reszel: None. L. Mastrandrea: Research Support; Current; Novo Nordisk, Rhythm Pharmaceuticals, Inc., Eli Lilly and Company. Research Support; Ended; Dompé. Research Support; Current; Cour. G.E. Wilding: None. Funding University at Buffalo Clinical and Translational Science Institute Pilot Studies Program. This program is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UM1TR005296 to the University at Buffalo, as well as: UB’s Office of the Provost, Office of the Vice President for Research and Economic Development, and Office of the Vice President for Health Sciences; Roswell Park Comprehensive Cancer Center; and the deans of UB’s Jacobs School of Medicine and Biomedical Sciences, School of Dental Medicine, School of Pharmacy and Pharmaceutical Sciences, School of Engineering and Applied Sciences, School of Public Health and Health Professions, and School of Nursing.
Quattrin et al. (Fri,) studied this question.